⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

July 8, 2026Clinical Nephrology

Rituximab improves the control of pediatric nephrotic syndrome and reduces healthcare utilization

Ahmed Zeid Melonie Phillips Christine Sethna Narla Deepti Aftab S. Chishti Helen Pizzo Hillarey Stone Jillian Warejko Larry Greenbaum William E. Smoyer John D. Mahan Mahmoud Kallash

View Full Paper

Ask AI

Bookmark

Share

Key Points

This study assesses the efficacy of rituximab in managing pediatric nephrotic syndrome and its effect on healthcare utilization.
Retrospective multicenter analysis of children with primary nephrotic syndrome treated with rituximab from 2013 to 2017.
Used summary statistics and statistical tests (Fisher's exact test, Mann-Whitney U test) for data analysis.
Included 50 children from 6 different treatment centers.
71.5% of steroid-sensitive nephrotic syndrome patients achieved sustained remission after treatment.
Median time to relapse was 16 months for steroid-sensitive and 7 months for steroid-resistant groups.
Hospital admissions per patient-year decreased from 0.53 to 0.11 after treatment with rituximab.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Retrospective study evaluates rituximab's efficacy in reducing nephrotic syndrome symptoms in children, implying significant healthcare benefits.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zeid et al. (2026) studied this question.

synapsesocial.com/papers/6a508d096eeac72a437a0d4c https://doi.org/10.5414/cn111986

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and safety of scheduled rituximab in children with refractory nephrotic syndrome after multi-target therapy failure2025
2[Clinical study on low-dose rituximab maintenance therapy in children with primary nephrotic syndrome].2025
3Low-dose rituximab followed by mycophenolate mofetil for steroid-dependent/frequently relapsing nephrotic syndrome in children: a case series2025 · 1 citations
4Rituximab therapy in adults with steroid-dependent nephrotic syndromeReview · 2019 · 4 citations
5Early Rituximab as an Add-On Therapy in Children With the Initial Episode of Nephrotic Syndrome2024 · 14 citations